The myeloma treatment pipeline continues to be busy with five treatments currently under review at NICE.
Many of the appraisals will be challenging but we will continue to work with key stakeholders to help myeloma patients access these effective treatments.
Hopefully this will lead more life-changing approvals from NICE and the Scottish Medicines Consortium (SMC).
Recent final decisions
Recommended by NICE: Daratumumab in combination with bortezomib (Velcade®), cyclophosphamide and dexamethasone for AL amyloidosis
In February 2024, Myeloma UK won their appeal against NICE’s decision not to recommend daratumumab plus bortezomib, cyclophosphamide and dexamethasone (DaraCyBorD) for newly diagnosed AL amyloidosis patients in England and Wales.
Over a year after the initial rejection of DaraCyBorD for AL amyloidosis by NICE, the treatment will soon be available on the NHS for newly diagnosed AL amyloidosis patients in England, Wales and Northern Ireland. It has been available for use in Scotland since its approval by the SMC in 2022.
Not recommended by the SMC: Belantamab mafodotin (Blenrep®)
In January, the SMC decided not to recommend belantamab mafodotin for relapsed and refractory myeloma patients who have had four or more prior lines of treatment and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Myeloma UK was involved in this appraisal and submitted evidence on behalf of patients in October 2023. We also attended the Patient and Clinician Engagement meeting in November 2023 and the Committee Meeting in December.
Forward look
Isatuximab (Sarclisa®), pomalidomide (Imnovid®) and dexamethasone.
The combination of isatuximab, pomalidomide and dexamethasone (IsaPD) is being reappraised by NICE for fourth-line myeloma patients.
NICE published a draft decision not to recommend the treatment for continued use on the NHS in England and Wales. Myeloma UK is involved in this reappraisal and responded to the consultation regarding the decision on behalf of patients on 1 March 2024.
The second NICE committee meeting took place on 14 March 2024. We continue to work with NICE and the pharmaceutical company to ensure patients in England and Wales can continue to access this treatment.
Selinexor (Nexpovio®), bortezomib and dexamethasone
The combination of selinexor plus bortezomib and dexamethasone (SVD) is being appraised by NICE for second- and third-line myeloma patients.
Myeloma UK is involved in this appraisal and responded to the consultation regarding the decision on behalf of patients in April 2024. The second NICE committee meeting took place on 7 March 2024. We hope to receive news of NICE’s final decision in the coming weeks.
Selinexor and dexamethasone
The combination of selinexor and dexamethasone is being appraised by NICE for myeloma patients who have received at least four previous treatments and who are refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody (penta-refractory).
Myeloma UK is involved in this appraisal and submitted evidence on behalf of patients in September 2023. The NICE committee meeting took place on 10 January 2024. We hope to receive news of NICE’s decision in the coming months.
Elranatamab monotherapy
Elranatamab monotherapy is being appraised by NICE for relapsed or refractory myeloma patients who have had at least three treatments including an immunomodulatory drug, a proteosome inhibitor and an antiCD38 monoclonal antibody (triple-class refractory).
Myeloma UK is involved in this appraisal and submitted evidence on behalf of patients in October 2023. The NICE committee meeting took place on 14 March 2024.
Teclistamab monotherapy
NICE are appraising teclistamab monotherapy for relapsed or refractory myeloma patients who have had three or more previous treatments.
Myeloma UK is involved in this appraisal and submitted evidence on behalf of patients in March 2024. The NICE committee meeting is scheduled for July 2024.
If you would like more information on HTA processes, upcoming treatment appraisals, or Myeloma UK’s access work, contact the Policy Team.